This was demonstrated by the significant inhibition of the cell cycle cyclin-dependent kinases (CDKs) like CDK1 (log2FC:-0.69; q-value=0.011), CDK2 and CDK3 (log2FC:-0.68; q-value=0.022), CDK7 (log2FC:-0.98; q-value=0.013), and CDK11 (log2FC:-0.52; q-value=0.011), and the decreased FAK and ERK3 activity (log2FC:-0.91; q-value=0.022), which both play a role in cell migration in cancer (36–39). The gene discussed is PTK2; the disease is cancer.